Latest filing published 30 Mar 2022 for Oragenics INC, €6,241.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -83.9%Entry US$612.00 · Close at T+365 US$98.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael O'Keefe Sullivan: trading record in brief
Michael O'Keefe Sullivan (finance chief) discloses dealings in Oragenics Inc to SEC (Form 4). Between 23 October 2012 and 29 March 2022, the trades on record add up to 7 filings.
Every open-market trade on record is a purchase: 1 purchase worth €6,241, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 6 share grants. So far in 2022, the count stands at 1 purchase and no sales.
On 30 March 2022 came the latest disclosure, an open-market purchase for €6,241 in Oragenics Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael O'Keefe Sullivan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,000 shares@ US$0.3461100.0% of flowCommon StockSEC:0001493152-22-008135:0Canonical exit: 27 Jun 2022 (T+90)
- 76,795 shares0Common StockSEC:0001209191-13-054675:0
- 26,795 shares@ US$3.00Common StockSEC:0001209191-13-054675:1
- 54,304 shares0Common StockSEC:0001181431-13-054780:0
- 19,000 shares@ US$2.99Common StockSEC:0001181431-13-054780:1
- 83,500 shares0Common StockSEC:0001181431-12-055506:0
- 26,261 shares@ US$2.10Common StockSEC:0001181431-12-055506:1
7 of 7 declarations